| abstract |
The attachment of H. influenzae to human cells, such as oropharyngeal cells, may be inhibited by native human beta -casein, a recombinant form of human beta -casein, and hydrolysates of both. The human beta -casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of otitis media in infants. The human beta -casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray. |